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Pharmacological targeting of the mammalian
clock regulates sleep architecture and emotional
behaviour
Subhashis Banerjee1, Yongjun Wang2, Laura A. Solt1, Kristine Griffett2, Melissa Kazantzis1,
Ariadna Amador1, Bahaa M. El-Gendy1, Salvador Huitron-Resendiz3, Amanda J. Roberts3,
Youseung Shin1, Theodore M. Kamenecka1 & Thomas P. Burris2

Synthetic drug-like molecules that directly modulate the activity of key clock proteins offer
the potential to directly modulate the endogenous circadian rhythm and treat diseases
associated with clock dysfunction. Here we demonstrate that synthetic ligands targeting a key
component of the mammalian clock, the nuclear receptors REV-ERBa and b, regulate sleep
architecture and emotional behaviour in mice. REV-ERB agonists induce wakefulness and
reduce REM and slow-wave sleep. Interestingly, REV-ERB agonists also reduce anxiety-like
behaviour. These data are consistent with increased anxiety-like behaviour of REV-ERBb-null
mice, in which REV-ERB agonists have no effect. These results indicate that pharmacological
targeting of REV-ERB may lead to the development of novel therapeutics to treat sleep
disorders and anxiety.
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C

ircadian rhythms play an essential role in aspects of
physiology and behaviour including the sleep–wake cycle,
body temperature, blood pressure and renal function. At
the molecular level, these circadian rhythms oscillate as a function
of a feedback loop in gene expression where heterodimers of
BMAL1 and CLOCK (or NPAS2) (the positive limb) activate the
expression of the Cryptochrome (CRY) and Period (PER) genes
(the negative limb). Once CRY and PER have reached a critical
level of expression, they are able to block the stimulatory effect
of the CLOCK/BMAL1 complex on their own promoters,
completing the loop. The nuclear receptors REV-ERBa and
REV-ERBb play an important role in regulation of the molecular
clock where they directly suppress the expression of genes of the
positive limb of the clock including CLOCK, BMAL1 and NPAS2
(refs 1–3). Rev-erba/Rev-erbb-deﬁcient mice display profound
alterations in circadian behaviour as well as expression of clock
genes4.
Normal oscillations in metabolic function are regulated by the
circadian clock, and disruption in the normal function of the
clock leads to metabolic disorders including diabetes, obesity and
atherosclerosis5–8. We recently demonstrated that synthetic
REV-ERB agonists altered both central and peripheral clock
gene expression, as well as modulated the metabolic state
in vivo9,10. Pharmacological activation of REV-ERB led to
increased energy expenditure, loss of fat mass and improved
plasma lipid proﬁles in mice9. We also observed increased oxidative
capacity in skeletal muscle in mice that was associated with
increased exercise endurance after treatment with a REV-ERB
agonist11. Thus, direct targeting of a molecular clock component
can alter the metabolic state and improve metabolic function.
Dysregulation of the circadian rhythm is associated with many
disorders including metabolic diseases and neuropsychiatric
disorders including bipolar disorder, anxiety, depression,
schizophrenia and sleep disorders12–15. In this report, we
examined the effects of REV-ERB agonists on patterns of sleep
and wakefulness, and found that the compounds increase
wakefulness. Furthermore, during this analysis we found that
the compounds also decreased anxiety-like behaviour. Thus, we
hypothesize that targeting components of the mammalian clock
with small molecules may provide therapeutics for treatment of
sleep disorders and anxiety disorders.
Results
Regulation of sleep by synthetic REV-ERB agonists. The
‘master’ circadian clock located in the suprachiasmatic nucleus of
the hypothalamus plays an essential role in regulation of sleep16
and given this close relationship, we sought to investigate the
effect of pharmacological activation of REV-ERB on patterns of
sleep and wakefulness. Although we observed alterations in
circadian wheel running activity previously9, the effect on sleep
was not clear. To investigate this, we administered a REV-ERB
agonist, SR9011, to mice and examined the effect on sleep and
wakefulness by electroencephalogram (EEG). As illustrated in
Fig. 1a, mice displayed a normal nocturnal proﬁle with low
wakefulness and high, slow-wave sleep (SWS) and paradoxical
sleep—rapid eye movement (REM) sleep during the daytime
(zeitgeiber time 0 (ZT0) to ZT12). Mice were administered
SR9011 (100 mg kg  1, intraperitoneally (i.p.)) or vehicle at ZT6
when Rev-erb expression is at its peak9. SR9011-treated mice
displayed a large increase in wakefulness that was maintained
for 2 h post injection (Fig. 1a, top panel). As expected, this
corresponded to a decrease in SWS and REM sleep during the
same time period (Fig. 1a, bottom panels). Latency to enter SWS
and REM sleep after administration of SR9011 was increased as
illustrated in Fig. 1b. At the onset of the dark period (ZT12),
2

vehicle-treated mice displayed a normal, rapid increase in
wakefulness (and decrease in SWS and REM sleep), while this
effect was delayed in SR9011-treated mice (Fig. 1a). A normal
pattern of sleep was observed after this recovery period B12 h
after the initial injection. Analysis of sleep architecture after the
single injection of SR9011 at ZT6 revealed effects on both SWS
and REM sleep architecture (Fig. 2). Following injection of
SR9011, the number of episodes of SWS increased while their
duration was shortened (Fig 2a,b). REM sleep was also affected
and was more impressive with REM sleep episodes and duration
being nearly completely suppressed for 3 h following
administration of SR9011 (Fig 2c,d). The sleep recovery period
that was observed following transition to dark was also observed
in the sleep architecture. Episodes of SWS were increased in
SR9011-treated mice from ZT13-15, while SWS duration
remained constant (Fig 2a,b). Episodes of REM sleep were also
elevated after transition to dark with SR9011 treatment (Fig. 2c).
No effect of SR9011 treatment was observed on EEG power
(Supplementary Fig. 1A).
In a separate experiment, we implanted mice with transmitters
to detect locomotion by telemetry. Using the same paradigm
(12 h:12 h light:dark (L:D) and injection at ZT6), we monitored
locomotor activity following injection of SR9011 or vehicle. Mice
receiving SR9011 displayed considerably more locomotor activity
following injection than vehicle consistent with an increase in
wakefulness (Fig. 1c). The telemetry units we used also enabled
measurement of core temperature and we assessed core
temperature under the same paradigm that we assessed sleep–
wakefulness patterns. As shown in Supplementary Fig. 2, we
observed the expected circadian pattern of body core temperature
with higher temperatures noted during periods of darkness that
are associated with wakeful mice. On administration of SR9011 or
vehicle at ZT6, we observed an abrupt increase in core
temperature, which we attribute to the waking of the animals
due to administration that we observed in the EEG as well
(Supplementary Fig. 2A). Following administration, mice treated
with vehicle displayed core temperatures that returned to levels
consistent with pre-administration levels; however, core temperatures in the SR9011-treated mice remained elevated relative
to vehicle-treated mice for B2 h (Supplementary Fig. 2A). This
elevation was B0.5 °C, which is smaller than the elevation
typically observed with wakefulness during the dark period.
Interestingly, there was no difference in core temperatures of
mice treated with vehicle or SR9011 during the dark period where
we have clearly observed a sleep recovery period by EEG. This
indicates that although the mice are recovering in terms of sleep,
the core temperature is elevated to levels equivalent to
wakefulness.
Next, we examined the effect of a REV-ERB agonist on sleep
patterns when administered during the animals’ wakeful period.
SR9011 or vehicle was administered to mice at ZT18, a time when
the percentage of mice in a wakeful state is very high. We
observed no distinction in sleep–wakefulness patterns between
SR9011 and vehicle treatment; furthermore, beginning at ZT0 the
mice entered their sleep phase normally (Fig. 1d). Latency to
enter SWS and REM sleep was unaffected when the REV-ERB
agonist was administered at ZT18 (Fig. 1e). Thus, our data
indicate that pharmacological activation of REV-ERB leads to
increased wakefulness, but this effect is dependent on the time of
day the compound is administered.
To further assess the speciﬁcity of this effect for REV-ERB
agonists, we examined the effects of a distinct synthetic REV-ERB
agonist, SR9009, on sleep architecture under L:D conditions. As
shown in Fig. 3a, the effect of SR9009 was very similar to SR9011
with induction of wakefulness and suppression of SWS and REM
sleep followed by a recovery period during the subsequent dark
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Figure 1 | SR9011 induces wakefulness and suppresses sleep. (a) Mice injected with The REV-ERB agonist SR9011 (i.p. 100 mg kg  1) at ZT6
display an increase in wakefulness as detected by EEG. (b) SR9011 increases SWS and REM sleep latency. (c) Locomotor telemetry data indicating an
increase in movement during the period 2 h after ZT6 injection of SR9011. (d) Mice injected with SR9011 (i.p. 100 mg kg  1) at ZT18 fail to demonstrate
increased wakefulness. (e) SR9011 does not alter SWS and REM sleep latency (ZT18 injection). Data are expressed mean±s.e.m. All EEG graphs are
plotted per 1 h for a 24-h period. Values are mean±s.e.m (n ¼ 8 for EEG studies (a,b,d,e) and n ¼ 6 for telemetry studies (c)). Within the EEG studies
(wakefulness, SWS and REM sleep), potential differences between treatments were assessed by repeated measure two-way analysis of variance (ANOVA)
followed by Bonferroni post hoc test. In panels examining latency and activity, differences between treatment groups (vehicle versus SR) were assessed
by a two-tailed Student’s t-test with signiﬁcance *Po0.05. In all experiments, mice were maintained on a 12 h:12 h L:D cycle.
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Figure 2 | Administration of SR9011 alters sleep architecture. Effect of SR9011 administered at ZT6 (analysis of data from Fig. 1a) on SWS
(number of episodes (a) and episode duration (b)), and on REM sleep (number of episodes (c) and episode duration (d)). Potential differences
between treatments were assessed by repeated-measures two-way ANOVA followed by Bonferroni post hoc test with signiﬁcance *Po0.05.
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Figure 3 | SR9009 induces wakefulness and suppresses sleep. (a) Mice injected with the REV-ERB agonist SR9009 (i.p. 100 mg kg  1) at ZT6 display an
increase in wakefulness as detected by EEG. (b) SR9009 increases SWS and REM sleep latency. (c) Locomotor telemetry data indicating an increase in
movement during the period 2 h after ZT6 injection of SR9011. Mice in a, b and c were maintained under 12 h:12 h L:D conditions. (d) Mice injected
with SR9009 (i.p. 100 mg kg  1) at CT6 under constant dark conditions show increased wakefulness. (e) SR9009 increases SWS and REM sleep
latency when injected at CT6 under constant dark conditions. Data are expressed as mean±s.e.m. All EEG graphs are plotted per 1 h for a 24-h period.
Values are mean±s.e.m. (n ¼ 8 for EEG studies and n ¼ 6 for telemetry studies). (c) Within the EEG studies (wakefulness, SWS and REM sleep),
potential differences between treatments were assessed by repeated measures two-way ANOVA followed by Bonferroni post hoc test.
In panels examining latency and activity, differences between treatment groups (vehicle versus SR) were assessed by a two tailed Student’s t-test
with signiﬁcance *Po0.05. Experiments were performed at least twice.

period. Latency to enter SWS and REM sleep was also extended
following SR9009 injection (Fig. 3b). Similar to SR9011-treated
mice, mice treated with SR9009 returned to normal patterns of
wakefulness/sleep 12 h after administration. Assessment of sleep
architecture revealed a similar proﬁle to that observed with
administration of SR9011. After administration of SR9009 at ZT6,
there was a general increase in episodes of SWS with a decrease in
episode duration (Fig. 4a,b). The only distinction between SR9011
and SR9009 is a short delay in the increased SWS episode number
where the number of episodes is actually decreased for one time
point. REM sleep is also similarly affected with REM sleep
episodes and episode duration suppressed following administration of SR9009 (Fig. 4c,d). The effect on sleep recovery was also
observed after SR9009 treatment where the number of episodes of
SWS and REM sleep were elevated after transition to the dark
period (Fig. 4a,c). No effect on EEG power was observed
(Supplementary Fig. 1B).
With this particular experiment, we continued to observe the
pattern of sleep–wakefulness for 48 additional hours to determine
whether there was any effect on circadian patterns of sleep.
4

As shown in Supplementary Fig. 3, we did not observe any
alterations in the pattern of sleep in response to SR9009 after the
ﬁrst day of administration. Assessment of core body temperature
following administration of SR9009 yielded similar results as did
SR9011 administration (Supplementary Fig. 2B). Immediately
following administration of SR9009, core temperature was
elevated, but not to levels that are normally associated with
wakefulness during darkness. In addition, as observed with
SR9011 administration, increased sleep after transition to the
dark period was not associated with lower core temperatures
(Supplementary Fig. 2B).
Assessment of locomotion by telemetry in mice injected with
SR9011 or vehicle revealed a response that was consistent with
increased wakefulness induced by SR9011 treatment (Fig. 3c).
Previously, we demonstrated that the effects of REV-ERB agonists
on wheel-running behaviour were distinct based on whether the
mice were maintained on a 12 h:12 h L:D cycle or in complete
darkness9. We performed an identical experiment to that
described in Fig. 3a monitoring EEG, except the animals were
maintained in complete darkness, which was initiated 2 days
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Figure 4 | Administration of SR9009 alters sleep architecture. Effect of SR9009 administered at ZT6 (analysis of data from Fig. 3a) on SWS
(number of episodes (a) and episode duration (b)) and on REM sleep (number of episodes (c) and episode duration (d)). Potential differences between
treatments were assessed by repeated measures two-way ANOVA followed by Bonferroni post hoc test with signiﬁcance *Po0.05.

before injection. The effects of SR9009 administration at CT6
under constant darkness were very similar to those obtained
under L:D conditions with increased wakefulness and decreased
SWS and REM sleep observed (Fig. 3d). Increased latency to enter
SWS and REM sleep following injection was also observed with
SR9009 treatment (Fig. 3e).
Regulation of anxiety by synthetic REV-ERB agonists. Polymorphisms in clock genes (RORA, CRY1, RORB, NR1D1, NPAS2,
CRY2, PER2, PER3 and BMAL1) have been linked to bipolar,
depressive and anxiety disorders in human17–24. Thus, the ability
to modulate the patterns of expression of the clock genes by the
REV-ERB agonists may provide a mechanism to inﬂuence these
disorders. Mice with a disrupted Clock gene display a behavioural
proﬁle similar to human mania that included hyperactivity,
decreased sleep, lowered anxiety and an increase in reward value
for cocaine25. A second group established that the Clock mutant
mice exhibited increased exploratory activity and escape seeking
behaviour consistent with lower levels of anxiety26. The positive
limb of the circadian clock is under direct positive transcriptional
control by the retinoic acid receptor-like orphan receptors27, and
consistent with loss of Clock gene expression associated with
reduced anxiety-like behaviour, mice harbouring a null mutation
in the Rorb gene also are less prone to display anxiety-like
behaviour28. These data suggest that targeting components of the
molecular clock may be an effective method to inﬂuence anxiety
behaviour. More speciﬁcally, based on the genetic data described
above, suppression of the positive limb of the clock, such as by
activation of REV-ERB activity, may suppress anxiety.
In previous experiments with S9011 and SR9009, where we
examined the effects of REV-ERB agonism on metabolic rate9
(chronic twice per day dosing (b.i.d.) (ZT0 and ZT12)), we noted
alterations in behaviour that suggested alterations in anxiety-like
behaviour. Based on the links between the circadian rhythm and
anxiety discussed above, as well as our preliminary observations,
we examined the effects of REV-ERB agonists on anxious
behaviour more closely. Mice were administered SR9011
chronically as was performed for previous assessments of effects
on metabolic parameters (3–10 days; 100 mg kg  1, b.i.d., i.p.;

details provided in the Methods as illustrated in Supplementary
Fig. 4) before beginning an open-ﬁeld assay to assess anxiety-like
behaviour. In an open-ﬁeld assay, mice treated with SR9011 spent
considerably more time in the centre of the ﬁeld, but displayed no
change in total distance travelled (Fig. 5a,b). This anxiolytic effect
was conﬁrmed in several other behavioural assays. Consistent
with the anxiolytic activity of SR9011, mice treated with the drug
spent considerably more time in the open arms in an elevated
plus maze (EPM) assessment (Fig. 5c). In addition, the mice
displayed a greater number of open-arm entries (Fig. 5d). We also
assessed the effect of SR9011 on neophobia exhibited by mice in a
novel object assay. Mice treated with SR9011 spent 6.5-fold more
time near the novel object consistent with anxiolytic activity
(Fig. 5e,f). Anxiolytic activity was also assessed in a light–dark
box assay and as shown in Fig. 5g. Mice administered SR9011
spent considerably more time in the light portion of the box,
again consistent with anxiolytic activity of the REV-ERB agonist.
Mice displayed no change in the number of transitions between
the two boxes in this assay (Fig. 5h). In a social interaction assay
(SIA) mice treated with SR9011 displayed increased interaction
with a novel mouse relative to vehicle-treated animals (Fig. 5i).
Finally, we assessed the effect of the drug in the marble-burying
assay, where mice are introduced into cages with marbles on the
surface of the bedding. Mice will naturally bury the marbles to
remove the stressful stimuli and effects of anxiolytics can be
readily assessed by reduced marble-burying activity. As
demonstrated in Fig. 5j, mice administered SR9011 buried only
50% of the marbles that mice administered vehicle did. This
anxiolytic effect was dose dependent (Fig. 5k) and the potency
(ED50 ¼ 61 mg kg  1) compares favourably with the potency of
SR9011 effects on circadian rhythm (ED50 ¼ 56 mg kg  1) and
gene expression in vivo (ED50 ¼ 67 mg kg  1)9. We also observed
anxiolytic activity of SR9009 in several of these assays (Fig. 5n-q).
The magnitude of effects we observed with SR9011 and SR9009
was similar to those observed when mice were treated with a
benzodiazepine (chlordiazepoxide) (Supplementary Fig. 5). These
data, taken together, suggest that pharmacological activation of
REV-ERB reduces anxiety-like behaviour while increasing
wakefulness rather than decreasing wakefulness, as do most
anxiolytic agents. Based on our initial observations of potential
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(c) and exhibit a greater frequency of open-arm entries (d) than vehicle-treated mice. Results from the novel object (neophobia) assay demonstrating that
SR9011-treated mice spend more time near the novel object (e) and travel more distance near the novel object (f) than vehicle-treated mice. Results from
the light–dark box assay demonstrating that mice treated with SR9011 spend considerably more time in the light box than vehicle-treated mice (g),
while displaying no difference in the total number of transitions between the boxes (h). Results for the SIA assay indicating that mice treated with SR9011
display greater social interaction with a novel mouse than mice treated with vehicle (i). Results from the marble-burying assay demonstrate that
SR9011-treated mice bury fewer marbles than vehicle-treated mice (j) and this effect is dose responsive (l). (l) Rev-erbb  /  mice display more anxiety in
the marble-burying assay consistent with data indicating that activation of REV-ERB leads to anxiolytic activity. (m) The REV-ERB agonist, SR9011,
does not display anxiolytic activity in Rev-erbb-null mice. Rev-erbb-null mice were treated with SR9011 in an identical manner as described in l and subjected
to the marble-burying assay, to examine the potential anxiolytic activity of SR9011. Consistent with the actions of SR9011, a distinct REV-ERB agonist,
SR9009, also reduces anxiety-like behaviour in the open-ﬁeld assay (n), the light–dark transition assay (o and p) and the marble-burying assay (q).
Values are mean±s.e.m., n ¼ 12 mice per group for all experiments, except the marble-burying test where n ¼ 8. With the exception of k, differences
between treatment groups (vehicle versus SR) were assessed by a two-tailed Student’s t-test with signiﬁcance *Po0.05. In k, differences between
groups were assessed using one-way ANOVA followed by Tukey’s post hoc test with signiﬁcance *Po0.05.

anxiolytic activity of SR9011 in chronically dosed mice in
metabolic studies, we performed the range of experiments
described above using chronically dosed mice. However, we
also examined the potential acute anxiolytic effect of SR9011 in
the marble-burying assay by administration of 100 mg kg  1
SR9011 followed by initiation of the 30-min assay 30 min after
administration. We observed no alteration in marble-burying
activity (data not shown), suggesting that chronic administration
is required for the anxiolytic activity.
6

We hypothesized that if the effects of SR9011 and SR9009 on
reducing anxiety-like behaviour were indeed mediated by REVERB, mice lacking the receptor may be more anxious, and that the
compound would lack activity in the null mouse. To investigate
this, we generated an nr1d2-null mouse (Supplementary Fig. 6)
and examined its activity in the marble-burying assay. As shown
in Fig. 5l, these mice displayed greater marble-burying activity
consistent with increased anxiety-like behaviour. Furthermore,
treatment of the null mice with SR9011 did not alter their
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which include reduced anxiety (elated mood) and increased
wakefulness, leading us to consider whether the REV-ERB
agonists may be inducing a behavioural proﬁle similar to
mania. Clearly, we observe reduced anxiety (Fig. 5) and
increased wakefulness (Figs 1 and 3). However, we do not
observe an effect on depression-like behaviour in a tailsuspension assay (Supplementary Fig. 7) and we also observe a
distinctly opposite effect on the reward value of cocaine (Fig. 6b).

CPP
4

Vehicle

Preference (post/pre)

CPP
1.2

Cocaine

Cocaine
+
SR9011

Figure 6 | REV-ERB activation alters reward-seeking behaviour.
(a) Results from a CPP assay indicating lack of CPP or aversion activity of
SR9011. Differences between treatment groups (vehicle versus SR) were
assessed by a two-tailed Student’s t-test with signiﬁcance *Po0.05.
(b) Results of a CPP assay indicating that SR9011 coadministration inhibits
the CPP displayed by cocaine. Differences between groups were assessed
using one-way ANOVA followed by Tukey’s post hoc test with signiﬁcance
*Po0.05. Values are mean±s.e.m., n ¼ 12 mice per group for all
experiments.

behaviour (Fig. 5m), indicating that the actions of the compound
were at least partially mediated by REV-ERBb.
REV-ERB agonists alter reward-seeking behaviour. Many
anxiolytics, such as benzodiazepines, are associated with abuse
liability related to their positive reinforcing ability. This can be
detected in rodents using a conditioned place preference (CPP)
assay29–32. We assessed the activity of SR9011 in the CPP assay
using an identical dose that displayed anxiolytic activity and
found no CPP or aversion (Fig. 6a), suggesting that anxiolytics
that target REV-ERB may display lower abuse potential than
benzodiazapenes. Interestingly, we previously noted that
administration of REV-ERB agonists results in loss of wheelrunning activity even though locomotor behaviour was not
affected9. The EEG data described above conﬁrm this
observation, demonstrating that the mice are wakeful and
exhibit locomotor activity during periods where we have
observed loss of wheel-running activity. This suggested that the
REV-ERB agonists might be altering motivation to run on the
wheel. Wheel running in rodents is a well-deﬁned rewarding
behaviour 33–35 and thus we hypothesized that REV-ERB agonists
may be interfering with the central reward pathway. To
investigate this, we performed an additional CPP assay where
we compared the effect of administration of cocaine alone with
coadministration of SR9011 with cocaine. As illustrated in Fig. 6b,
a clear condition place preference was observed with cocaine that
was inhibited by coadministration of SR9011. These data suggest
that REV-ERB agonists suppress the rewarding behaviour
associated with wheel running and cocaine, yet the agonist by
itself does not induce aversive behaviour.
Mice harbouring a mutation in the clock gene have been shown
to display a behavioural proﬁle similar to human mania25.
Furthermore, polymorphisms in the human gene encoding
REV-ERBa (NR1D1) are associated with bipolar disorder21. As
previously discussed, REV-ERB agonists would be expected to
reduce clock expression levels and may mimic the effect observed
in these mice. According to the Diagnostic and Statistical Manual
of Mental Disorders, Fifth Edition, a manic episode in humans is
characterized by the presence of at least three symptoms of seven,

SR10067 is a novel REV-ERB agonist with high afﬁnity. SR9011
and SR9009 were the ﬁrst synthetic REV-ERB agonists developed
with sufﬁcient pharmacokinetic properties, to be used as in vivo
chemical tools9. However, they exhibit relatively low potency for
the receptor with IC50’s of B700 nM9. We hypothesized that if
activation of REV-ERB with synthetic agonists did indeed lead to
the wakefulness and anxiolytic effects, development of higherafﬁnity REV-ERB agonists with either equivalent or improved
pharmacokinetic properties should yield improvements in the
in vivo potency. To test this hypothesis, we evaluated a synthetic
REV-ERB agonist (SR10067) derived from extensive modiﬁcation
of the SR9009/SR9011 scaffold36,37 (Fig. 7a and Supplementary
Figs 8 and 9) that displays substantially greater potency than
SR9011 and SR9009 in vitro. The potency of SR10067 is
considerably better than SR9011 and SR9009 in the Gal4DBDREV-ERB ligand-binding domain cotransfection assay (SR10067:
REV-ERBa IC50 ¼ 170 nM, REV-ERBb IC50 ¼ 160 nM (Fig. 7b)
versus SR9011: REV-ERBa IC50 ¼ 670 nM, REV-ERBb
IC50 ¼ 800 nM9). Potency of SR10067 was also considerably
better in a cotransfection assay using full-length REV-ERBa along
with the BMAL1 promoter luciferase reporter (SR10067
IC50 ¼ 140 nM (Fig. 8c) versus SR9011 IC50 ¼ 620 nM9).
SR10067 displayed no signiﬁcant activity at any other nuclear
receptor (Fig. 7e) or a range of other receptors, ion channels and
transporters assessed in the NIMH Psychoactive Drug Screening
Program (Supplementary Table 1. Assessment of plasma and
brain concentrations of SR10067 1 and 6 h after i.p. injection
(30 mg kg  1) revealed that levels of the compound remain above
the IC50 for the receptor 6 h after administration (Fig. 7d). As a
marker of in vivo efﬁcacy of REV-ERB agonists, we previously
demonstrated that a single injection of SR9011 or SR9009
suppressed the circadian rhythm of Npas2 gene expression in the
mouse hypothalamus9, and when we performed this experiment
with SR10067 we observed similar results (Fig. 7f). Synthetic
REV-ERB agonists also suppress circadian wheel-running activity
after a single injection9 and this was observed with SR10067. As
illustrated in Fig. 8a,b, administration of SR10067 at various
concentrations yielded a dose-dependent effect on reduction in
nocturnal wheel-running activity as indicated in the actograms.
The ED50 for suppression of wheel-running activity was
20 mg kg  1 (Fig. 8b), which is more potent than that described
for SR9011 (56 mg kg  1)9 and is consistent with the improved
potency of SR10067 in the REV-ERB transcriptional assays.
SR10067 induced wakefulness and reduced SWS and REM sleep
when injected at ZT6, similar to what was observed with SR9011
and SR9009 (Fig. 8c). The effect of SR10067 on sleep architecture
was also similar to what was observed with SR9011 and SR9009,
with increased number of episodes of SWS with decreased
duration and decreased number of episodes and duration of REM
sleep (Fig. 9). No effect on EEG power was observed
(Supplementary Fig. 1C). SR10067 also induced locomotion
when administered into mice at ZT6 in a manner similar to
SR9009 and SR9011, consistent with an increase in wakefulness
(Fig. 8d). The anxiolytic activity of SR10067 was assessed in the
marble burying anxiety assay and SR10067 displayed superior
potency than SR9011 (ED50 of 12versus 61 mg kg  1) (Fig. 8e).
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Figure 7 | Identiﬁcation of SR10067 as a highly potent synthetic REV-ERB agonist. (a) Chemical structure of the synthetic REV-ERB agonist SR10067
compared with SR9011 and SR9009. (b) Results from a Gal4-REV-ERB/Gal4 UASX5 luciferase reporter co-transfection assay in HEK293 cells displaying
the potent REV-ERB agonist activity of SR10067. (c) Results from a co-transfection assay in HEK 293 cells with full-length REV-ERBa and a BMAL1
promoter-driven luciferase reporter displaying the potent agonist activity of SR10067. (d) Plasma and brain concentrations of SR10067 2 h following i.p.
injection of 30 mg kg  1 of the compound. The 6-h value for SR10067 in the brain is 150±20 nM. (e) Nuclear receptor speciﬁcity assay illustrating lack of
activity of SR10067 on a wide range of nuclear receptors. The format of the assay was a co-transfection assay with Gal4 DNA-binding domain–nuclear
receptor fusions in HEK293 cells as previously described (see Methods). SR10067 was tested at 20 mM. Error bars indicate mean±s.e.m. and n ¼ 3. There
were no statistical differences between vehicle and drug treatment in any of the assays shown as assessed by a Student’s t-test (unpaired two-tailed).
(f) Normalized (to Gapdh) expression of Npas2 mRNA isolated from the hypothalamic of mice injected with 30 mg kg  1 of SR10067 (i.p. at ZT0)
demonstrating a SR10067-dependent alteration in the circadian rhythm of expression. Expression was monitored over 24 h and the results are double
plotted. n ¼ 5. *Po0.05. Mean±s.e.m.

This ﬁvefold improvement in in vivo anxiolytic potency compares
favourably with the in vitro improvement in potency (four- to
ﬁvefold) when comparing SR10067 with SR9011. These data
clearly suggest that the anxiolytic activity is mediated by
activation of REV-ERB given that two synthetic REV-ERB
selective agonists, with distinct chemical structures, display
anxiolytic activity that correlates to their relative activity at
REV-ERB.
Discussion
The mammalian clock maintains the circadian rhythm that is
essential for normal physiological function. Mutation of components of the clock alters normal physiological processes at
multiple levels including sleep, metabolism, behaviour and so
on7,38,39. Alteration of the normal circadian rhythm in humans
due to shift work or experimental manipulation alters the
metabolic and mental health of individuals. In addition,
8

circadian disruption is commonly noted in a range of
psychiatric disorders including anxiety, schizophrenia and
depression12–15. It has been unclear whether molecular
components of the mammalian clock could be targeted for
development of therapeutics, and recently small molecule
regulators of the core clock have been discovered and
developed10,40. Small molecule inhibitors41 and activators42 of
CRY have been discovered and they regulate the circadian
rhythm in cell lines, but none have progressed to evaluation in
animal models to determine their potential utility for treatment of
disease. It has been suggested that REV-ERB be considered as a
core component of the clock, as mice lacking both REV-ERBa
and REV-ERBb are arrhythmic4. Our recent study demonstrated
that synthetic REV-ERB agonists alter the circadian rhythm and
improve the metabolic proﬁle in mouse models of metabolic
disease. Here we show that pharmacological targeting of the core
clock has further value, demonstrating the ability of REV-ERB
agonists to modulate sleep and emotional behaviour.
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Figure 8 | SR10067 alters sleep architecture and anxiety-like behaviour. (a) Actograms from wheel-running cages demonstrating the effect of
SR10067 injection (red bars, i.p. various concentrations) on wheel-running activity in mice. (b) Assessment of the dose dependence of inhibition of
wheel-running activity in mice during the entire dark phase following administration of SR10067. n ¼ 6–8 mice per group. (c) Assessment of the effect
of SR10067 on wakefulness in mice. Wakefulness, SWS and REM sleep was monitored by EEG as indicated in Figs 1 and 2. Mice were injected with
SR10067 (30 mg kg  1, i.p.) or vehicle at ZT6. n ¼ 8 mice. (d) Locomotor telemetry data indicating an increase in movement of mice during the period 2 h
after ZT6 injection of SR10067 (30 mg kg  1). n ¼ 6 mice. (e) Results from the marble-burying assay demonstrating that SR10067 dose dependently
reduces anxiety-like behaviour in the marble-burying assay. n ¼ 8 mice. Values are mean±s.e.m. In d, differences between treatment groups (vehicle
versus SR) were assessed by a two tailed Student’s t-test () with signiﬁcance *Po0.05. In b and e, differences between groups were assessed using
one-way ANOVA followed by Tukey’s post hoc test with signiﬁcance *Po0.05. In c, potential differences between treatments
were assessed by repeated-measures two-way ANOVA followed by Bonferroni post hoc test with signiﬁcance *Po0.05.

In mice treated with various REV-ERB agonists, we observed
alterations in patterns of sleep–wakefulness, sleep architecture
and the level of anxiety. Clock genes have been demonstrated to
play an important role in regulation of sleep. Bmal1-null mice
display increased sleep and this sleep displays increased
fragmentation43. Clock mutant mice display reduced non-REM
sleep, while Cry1/Cry2-null mice display an increase in non-REM
sleep44,45. Npas2-null mice as well as Per-null mice also display
alterations in the patterns of sleep46–48. Given the role that
REV-ERB plays in regulation of these genes, we believed there
would be an effect of pharmacological modulation of REV-ERB
activity on sleep. All of the studies examining the effect of clock
genes on sleep are genetic loss of function studies and not
pharmacological studies; thus, we were not sure what to expect
with the ﬁrst examination of pharmacological targeting of a clock

gene on sleep. Administration of REV-ERB agonists stimulates
wakefulness and suppresses sleep. This effect is acute, which is
consistent with the short half-life of the compounds, and the mice
return to a normal sleep pattern within B12 h. The lack of effect
on long-term circadian behaviour is consistent with our previous
data indicating that REV-ERB agonists only transiently altered
circadian wheel-running behaviour followed to a return to a
normal circadian rhythm9. Sleep disorders affect B70 million
individuals in the United States and therapeutics such as the
REV-ERB agonists that induce wakefulness while also reducing
anxiety should be examined for treatment of shift work–sleep
disorder and sleep apnoea.
Previously, we demonstrated that REV-ERB agonists increase
the metabolic rate and are quite effective in increasing oxidative
metabolism in skeletal muscle9,11. This would probably be
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Figure 9 | Administration of SR10067 alters sleep architecture. Effect of SR10067 administered at ZT6 (analysis of data from Fig. 9c) on SWS (number
of episodes (a) and episode duration (b)) and on REM sleep (number of episodes (c) and episode duration (d)). Potential differences between treatments
were assessed by repeated-measures two-way ANOVA followed by Bonferroni post hoc test with signiﬁcance *Po0.05.

associated with an increase in core body temperature; however, a
recent study also demonstrated that Ucp1 is a direct REV-ERB
target gene, and that in brown adipose tissue loss of REV-ERBa
leads to a decrease in thermogenic brown adipose tissue activity49.
Thus, it was unclear what the summation of effect of
pharmacological activation of REV-ERB on core body
temperature would be. We observed that pharmacological
activation of REV-ERB led to a transient increase in core body
temperature when administered at ZT6, but the elevation of
temperature was not equivalent to that observed during normal
wakefulness in the dark period. Interestingly, in the transition to
darkness when mice administered REV-ERB agonists displayed
sleep recovery, they also displayed an increase in body core
temperature that was indistinguishable from mice administered
vehicle that displayed normal wakefulness. Alterations in sleep
and wakefulness have been associated with changes in cellular
energetics50, and although modulation of REV-ERB activity
may indeed alter patterns of sleep and wakefulness by altering
cellular energetics, we observed that these can be uncoupled,
at least in terms of gross measurements of body core temperature.
Even more intriguing is our observation that REV-ERB
agonists reduced anxiety-like behaviour in mice in an array of
behavioural assays that are models of generalized anxiety disorder
and social anxiety disorder51. Although there is data to suggest
that the mammalian clock is involved in anxiety, there have been
no chemical tools available until recently, to effectively address
the potential to alter the central anxiety pathways by altering the
clock. Anxiety disorders are among the most common mental
disorders and nearly 30% of individuals will be directly affected
by an anxiety disorder at some point in their lifetime; thus, these
disorders signiﬁcantly burden our society52–54. Given the
predominance of anxiety disorders in our society, there
continues to be a focus on development of novel anxiolytic
agents with improved efﬁcacy and/or side-effect proﬁles. Clearly,
the pharmacological proﬁle of these compounds is paradoxical,
given their ability to combine anxiolytic activity with increased
wakefulness, which could offer a clear clinical advantage under
many circumstances. Drugs that typically increase arousal also
increase anxiety (forexample, cocaine and amphetamines), while
drugs that decrease anxiety decrease arousal (for example,
benzodiazepines and ethanol)55. Exceptions to this proﬁle
include nicotine56 and Neuropeptide S57, but the
10

pharmacological proﬁle of REV-ERB agonists and their ability
to target the clock appear to be distinct from these pathways.
It is also important to note that SR9011 inhibited the condition
place preference associated with cocaine-induced reward without
itself inducing aversion. Our data indicating that mice treated
with various REV-ERB agonists failed to wheel run during
periods when they were awake led us to hypothesize that there
may be suppression of reward-seeking behaviour. Drug addiction
clearly has a circadian component58 and mice with mutations in
clock genes such as Per1, Per2, Clock and Npas2 have altered
responsiveness to the reward associated with cocaine, morphine
and/or alcohol25,59–61. Thus, it is quite reasonable to expect that a
small molecule regulator of the clock would modulate rewardseeking behaviour. These data suggest that modulation of the
clock by small molecule drugs, such as REV-ERB agonists, may
have utility in treatment of addiction.
Using a variety of approaches including mouse genetic models,
epidemiology, clinical research, circadian rhythms and the
underlying molecular clock mechanism have been associated
with a variety of disorders. With recent chemical biology
approaches, it has become possible to target certain components
of the clock and begin to investigate whether pharmacological
modulation of clock function and the circadian rhythm may offer
an approach to treat human disease. In summary, our data
indicate that pharmacological targeting of the clock holds
promise for treatment of disorders associated with anxiety and
sleep disorders, as well as addiction.
Methods
Synthesis and preparation of SR9011 and SR9009. SR9011 and SR9009 were
prepared as previously described9.
Synthesis and preparation of SR10067. DL-(1,2,3,4-tetrahydroisoquinolin-3-yl)
methanol. DL-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (3.54 g, 20 mmol)
was added portion wise to a suspension of LiAlH4 (3.04 g, 80 mmol) in tetrahydrofuran (150 ml) at 0 °C under argon. The reaction mixture was heated under
reﬂux for 16 h. It was then cooled to 0 °C, and water (3 ml), 15% aqueous NaOH
(3 ml) and water (9 ml) were added under stirring. The precipitate was then ﬁltered
and washed with diethyl ether (3  100 ml). The solvent was removed under
vacuum and the product obtained as brown microcrystals (76%) was used in the
next step without further puriﬁcation. 1H NMR (400 MHz, CDCl3): d (p.p.m.)
7.18–7.05 (m, 3H), 7.06–7.00 (m, 1H), 4.05 (s, 2H), 3.76 (dt, J ¼ 10.9, 3.1 Hz, 1H),
3.51 (dd, J ¼ 10.8, 7.9 Hz, 1H), 3.05 (ddq, J ¼ 11.3, 7.4, 3.7 Hz, 1H), 2.69 (dt,
J ¼ 16.3, 3.4 Hz, 1H), 2.57 (dd, J ¼ 16.4, 10.8 Hz, 1H); 13C NMR (100 MHz,
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CDCl3): d (p.p.m.) 135.6, 134.1, 129.4, 126.4, 126.2, 126.0, 65.7, 55.2, 48.0, 31.1;
high-resolution mass spectroscopy (HRMS) calculated for C10H13NO (M þ H) þ :
164.1069, found: 164.1051.
(3-(Hydroxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl)(naphthalen-1-yl)
methanone. To a solution of DL-(1,2,3,4-Tetrahydroisoquinolin-3-yl)methanol
(0.816 g, 55 mmol) in dicholoromethane was added 1-naphthoyl chloride (0.908 ml,
6 mmol), and triethylamine (1.36 ml, 10 mmol) and the mixture was stirred for
12 h. The reaction mixture was washed with HCl (2 N), saturated sodium
bicarbonate solution and brine. The organic phase was separated, dried over
anhydrous MgSO4 and the solvent was removed under reduced pressure. The
residue was then puriﬁed by ﬂash chromatography on silica gel (ethyl acetate/
hexanes) to give the title compound as light-brown microcrystals (78.8%). 1H
NMR (400 MHz, Chloroform-d) d (p.p.m.) 1H NMR (400 MHz, CDCl3): (mixture
of rotamers) d (p.p.m.) 8.05 (t, J ¼ 9.5 Hz, 0.6H), 7.98–7.76 (m, 2.4H), 7.64–7.44
(m, 3.4H), 7.37 (dd, J ¼ 20.3, 7.5 Hz, 1H), 7.25–7.17 (m, 2H), 7.16–7.01 (m, 1H),
6.75–6.62 (m, 0.5H), 5.69–5.58 (m, 0.5H), 5.33–5.20 (m, 0.5H), 4.59–4.00 (m, 2H),
3.96–3.72 (m, 1H), 3.64–3.48 (m, 0.5H), 3.30–3.10 (m, 1H), 3.04–2.79 (m, 1H),
2.68–2.51 (m, 0.5H); 13C NMR (100 MHz, CDCl3): (mixture of rotamers) d
(p.p.m.) 172.12, 171.33, 134.57, 134.50, 133.60, 133.35, 132.75, 131.51, 129.58,
129.53, 129.45, 129.32, 129.09, 128.92, 128.62, 128.55, 128.49, 128.33, 127.57,
127.49, 127.13, 127.08, 126.89, 126.74, 126.71, 126.65, 126.58, 126.49, 126.45,
125.70, 125.54, 125.37, 125.33, 125.16, 124.76, 124.48, 123.77, 63.81, 63.63, 61.66,
61.22, 54.39, 51.36, 51.32, 46.36, 42.05, 41.31, 41.22, 30.23, 30.07, 29.86, 29.82;
HRMS calculated for C21H19NO2 (M þ H) þ : 318.1489, found: 318.1491.
(3-((4-(Tert-butoxy)phenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)
(naphthalen-1-yl)methanone. To a solution of (3-(hydroxymethyl)-3,4dihydroisoquinolin-2(1H)-yl)(naphthalen-1-yl)methanone (0.317 g, 1 mmol),
triphenylphosphine (0.288 g, 1.1 mmol) and 4-(tert-butoxy)phenol (0.166 g,
1 mmol) in dry toluene (2 ml) at 0 °C was added diisopropyl azodicarboxylate
(0.216 ml, 1.1 mmol) dropwise. The mixture was stirred at ambient temperature
overnight. The solvent was evaporated and the residue was then puriﬁed by ﬂash
chromatography on silica gel (ethyl acetate/hexanes) to give the title compound as
a white microcrystals (50%). 1H NMR (400 MHz, CDCl3): (mixture of rotamers) d
8.23–8.12 (m, 0.5H), 7.98–7.82 (m, 2H), 7.76–7.41 (m, 4H), 7.34–7.06 (m, 4H),
7.02–6.83 (m, 2H), 6.79–6.63 (m, 2H), 6.50–6.42 (m, 0.5H), 5.82–5.52 (m, 1H),
4.60–4.36 (m, 1H), 4.35–4.10 (m, 2H), 3.92 (dt, J ¼ 12.6, 9.5 Hz, 0.5H), 3.70 (ddd,
J ¼ 31.9, 9.8, 6.1 Hz, 0.5H), 3.35 (dd, J ¼ 16.3, 6.3 Hz, 0.5H), 3.31–3.05 (m, 1H),
2.84–2.61 (m, 0.5H), 1.36–1.25 (m, 9H); 1H NMR (400 MHz, d6-DMSO, 110 °C): d
8.0 (d, 2H), 7.8 (br s, 1H), 7.62–7.58 (m, 4H), 7.2 (br s, 3H), 7.0–6.5 (br m, 4H), 5.5
(br s, 1H), 4.5–3.7 (m, 4H), 3.3–2.8 (m, 2H), 1.3 (s, 9H); 13C NMR (100 MHz,
CDCl3): (mixture of rotamers) d (p.p.m.) 171.11, 171.07, 170.58, 154.88, 154.50,
154.30, 149.13, 149.10, 148.93, 134.38, 132.83, 129.41, 127.02, 126.91, 126.87,
125.56, 125.53, 125.47, 125.27, 114.86, 114.72, 114.51, 114.37, 78.31, 78.29, 78.21,
67.16, 66.79, 52.57, 52.03, 47.81, 41.28, 41.20, 34.79, 30.73, 28.85, 28.79, 28.77,
22.78, 22.08, 14.26; 13C NMR (100 MHz, d6-DMSO, 110 °C): 169.8, 154.5, 149.5,
135.1, 133.6, 129.2, 128.7, 127.2, 126.7, 126.6, 125.6, 124.8, 124.2, 115.4, 77.8, 67.8,
52.3, 30.1, 29.0; HRMS calculated for C31H31NO3 (M þ H) þ : 466.2376, found:
466.2373.
Pharmacokinetic studies. Pharmacokinetic studies were performed as previously
described1.
Co-transfection assays. Co-transfection assays were performed as previously
described in HEK293 cells (Gal4cotransfection assay) or in HepG2 cells (full-length
nuclear receptors)1. Cells were recently obtained from the ATCC (within four
passages) and monitored for mycoplasma contamination.
Mice. C57BL6 and Balb/c male mice were obtained from the Jackson Laboratories
(Bar Harbor, ME). All the procedures were conducted in the Scripps or SLU
vivarium, which are fully accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care, and were approved by the Scripps
Institutional Animal Care and Use Committee and the SLU Institutional Animal
Care and Use Commitee. All experiments were conducted at 22–23 °C.
Compound administration. For all experiments, 8-week-old C57BL6/J or Balb/c
male mice were administered doses of SR9011 or SR9009 100 mg kg  1 (i.p., b.i.d.)
for 3–10 days for behavioural assays. See Supplementary Fig. 5 for a schematic of
the dosing and testing regimen. For twice per day dosing, dosing was performed at
ZT0 and ZT12. For the ﬁrst testing regimen open-ﬁeld assay, light–dark transfer
assay, marble-burying assay and tail-suspension assays were performed after 3, 5, 8
and 10 days of dosing, respectively. These assays were typically performed 1–2 h
after the ZT12 injection under red light. However, the open-ﬁeld and marbleburying assays were also performed at ZT6–8 and under normal light conditions
with no distinction in efﬁcacy of SR9011, indicating that the anxiolytic action was
not time of day dependent. For the second regimen, the novel object and EPM
assays were performed after 3 and 5 days of twice per day dosing, respectively, at
ZT 6–8 under normal light conditions. Initially, multiple assays were performed in
this manner so as to allow the same cohort of animals to be examined in multiple
assays. However, if single assays were run, the identical dosing regimen was

employed for consistency. The CPP and SIA assay were performed after 5 days of
dosing. SR10067 was administered at various doses as indicated in the ﬁgure
legends. The speciﬁcs of administration of compounds for sleep studies is indicated
in the ﬁgures/ﬁgure legends. Formulation of the REV-ERB agonists was performed
as previously described9. For studies where LiCl was used, mice were provided LiCl
in drinking water (600 mg l  1), while control mice received normal water for
10 days before initiation of the study. The LiCl drinking water was maintained
during the study. For studies using cocaine, Cocaine hydrochloride (National
Institute on Drug Abuse) was dissolved in sterile 0.9% saline solution. Mice were
administered 10 mg kg  1 cocaine in the CPP studies and doses as indicated in the
ﬁgure in the EEG studies.
Gene targeting. Standard gene targeting procedures62 were used to generate mice
with ﬂoxed alleles at the Rev-erbb locus on a C57BL6/6J background. The ﬂoxed
Rev-erbb mice were generated at the transgenic core at the Pennington Biomedical
Research Center in Baton Rouge, LA. The strategy for generation of the mice is
shown in Supplementary Fig. 7A. For generation of the germ line-deleted strain,
the ﬂoxed Rev-erbb mice were mated with Ella-Cre mice.
Open-ﬁeld and neophobia assays. Mice were handled 2 min daily for 3 days
before testing their spontaneous locomotor activity and reactivity to novelty in an
activity chamber. The chamber where the mice were assessed is a rectangle
(37 cm  57 cm) that is divideded into nine virtual zones of identical size
(B12 cm  19 cm zones). The open-ﬁeld assay was initiated by placing the mice in
the centre of the chamber. The locomotor activity was monitored by a video
camera mounted on the ceiling and a computerized tracking system (Ethovision
1.90, Noldus IT, Wageningen, The Netherlands) recorded the total distance moved,
speed and percentage of time spent in each zone. Time occupied in the centre zone
(B12 cm  19 cm) and latency to enter the centre zone was assessed for the openﬁeld assay as well as total distance travelled. For the neophobia assay, mice that had
already been assessed in the open-ﬁeld assay and thus familiar with the chamber
were placed into the centre of the chamber to which a novel object had been ﬁxed.
The novel object was a 7 black rubber stopper placed at the top centre of the
chamber (zone 2 if one considers the activity box consisting of three rows of three
zones) and the reactivity of the animal towards the object was measured. Zone 2
was considered near the novel object and time spent in this zone was scored. The
ﬂoor of the arena and the object were washed after each test, with 70% ethanol
solution to remove odours left by previous subjects.
Elevated plus maze. Anxiety-like behaviour of mice were evaluated using the
EPM test. The EPM consisted of two opposing open arms (45 cm  10 cm) and two
closed arms (45 cm  10 cm  50 cm) that extended from a central platform
(10 cm  10 cm) elevated 65 cm above the ﬂoor. Mice were placed individually on
the central platform facing a closed arm and were allowed to freely explore the
maze for 5 min. The behaviour of each mouse was monitored using a video camera
and the movement of the mice automatically registered and analysed with a
computerized tracking system (Ethovision 1.90, Noldus IT). Entry into an arm was
deﬁned as entry of all four paws into the arm. Total distance moved, speed, time
spent in the open and closed arms, number of times the animal entered each type
of arm and latency before entering an open arm were measured. Animal’s
grooming, stretching and rearing behaviours, as well as the exploration outside the
maze (head dipping), were measured. The ﬂoor of the EPM was washed after each
testing with 70% ethanol solution to remove odours left by previous subjects.
Marble-burying assay. The marble-burying test is used to assess anxiety-like
behaviour in a less vision-dependent manner than other available tests such as the
EPM and light/dark transfer tests. Mice were placed individually in a standard
mouse cage containing bedding that is 5 cm in depth, with 20 small marbles
arranged in 4 evenly spaced rows of 5 on top of the bedding material as previously
described57. After 30 min, mice were removed and the number of marbles buried
(at least two of three covered by bedding) is determined. Increased marble burying
is associated with increased anxiety-like behaviour in tests of anxiety medications.
Light–dark box assay. The light–dark transfer procedure has been used to assess
anxiety-like behaviour in mice by capitalizing on the conﬂict between exploration
of a novel environment and the avoidance of a brightly lit open ﬁeld57. The
apparatus is a rectangular box made of Plexiglas divided by a partition into two
environments. One compartment (14.5  27  26.5 cm) is dark (8–16 lux) and the
other compartment (28.5  27  26.5 cm) is highly illuminated (600–800 lux) by a
60-W light source located above it. The compartments are connected by an
opening (7.5  7.5 cm) located at ﬂoor level in the centre of the partition. The time
spent in the light compartment was used as a predictor of anxiety-like behaviour,
that is, a greater amount of time in the light compartment was indicative of
decreased anxiety-like behaviour. Mice were placed in the dark compartment to
start the 5-min test.
Conditioned place preference assay. Studies were conducted using a threecompartment apparatus with two equal-sized chambers (17  12.7  12.3 cm)
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separated by a neutral gray chamber (8.5  12.7  12.3 cm) (ENV-3013; Med
Associates, St Albans, VT). The large compartments differed in the wall colour
(black or white) and ﬂooring (wire bars or wire mesh), and were separated from the
centre gray compartment by sliding doors. Mice were ﬁrst assessed for baseline
preference across two 30-min sessions. Each animal was placed in the centre gray
chamber and permitted to freely move through the chambers. Time spent in each
chamber was recorded using Med PC software. Based on the time spent in either
the white or black chamber during the baseline sessions the non-preferred chamber
was assigned as the drug-paired chamber, while the preferred chamber was paired
with saline. Mice were subsequently trained across 6 consecutive days. For each
session, animals were injected with either the drug or vehicle 15 min before being
conﬁned to the assigned white or black chamber for 30 min. Injection and chamber
pairings were counterbalanced across training sessions. On the ﬁnal test day,
mice were placed in the centre gray compartment and permitted to freely move
throughout the apparatus for 30 min. The time spent in each chamber was
recorded as above and the data from the test day were compared with the baseline
level to obtain a preference score (post training/pre training).
Electroencephalogram. EEG analysis was performed as previously described63–66.
EEG data are recorded from stainless steel screw electrodes implanted on the
frontal and parietal bone over the hippocampus (coordinates: 2.0 mm posterior and
2.0 mm lateral to the bregma according to The Mouse Brain in Stereotaxic
Coordinates from Franklin and Paxinos, 1977), and under general anaesthesia
(1–1.5% isoﬂurane). A fourth EEG electrode is implanted over the cerebellum,
which is used to ground the animal to reduce signal artefacts. Insulated leads from
the EEG electrodes are crimped to male pins (220-P02) and then cemented to
the skull with dental acrylic. Following surgical implantation, mice are allowed
1–2 weeks to recover before the study. To record EEG, mice are connected to
commutators (PlasticOne) with ﬂexible recording cables allowing them
unrestricted movements within the cage and habituated to the recording cages for
48 h. Compounds were administered and recording was continued for another
48 h. The EEG and electromyography signals were ampliﬁed in a Grass Model 7D
polygraph in a frequency range of 0.3 to 10 KHz. The EEG and EMG are displayed
on a computer monitor and stored with a resolution of 128 Hz in the hard drive of
a computer for the ofﬂine analysis of the vigilance states and spectral analysis using
software supplied by Kissei Comptec. The polygraphic results are analysed semiautomatically by 15-s epochs and classiﬁed as W, SWS and REM sleep. The total
time of these vigilance states is calculated in periods of 1 h. The number and
duration of the individual W, SWS and REM sleep episodes are evaluated. In
addition to standard sleep analysis, EEG spectral analysis in the different states of
vigilance is performed by Fourier fast transformer analysis using 4-s epochs instead
of the 15-s epochs.
Tail suspension test. The tail suspension test was carried out essentially as previously described by Steru et al.67 Mice were allowed to acclimatize to the holding
room for 30 min before the behavioural procedure. One hour after the ﬁnal
administration of vehicle or SR9011, mice were individually suspended by the tail
from each of the hooks of the tail suspension test apparatus using adhesive tape
placed about one-third away from the tip of the tail. Immobility duration was
recorded for 6 min after 1 min of acclimatization. Mice were considered immobile
only when they hung passively and completely motionless. The duration of
immobility during the 6-min test period was automatically recorded by a camera
and stored on a computer equipped with EthoVision XT software.
Telemetric assessment of locomotor activity and core body temperature. The
Physiotel TA-F10 transmitters (Data Sciences International, USA) were surgically
implanted to the peritoneal cavity of mice under constant general isoﬂuorane
anaesthesia (1–1.5%). The implanted mice were allowed to recover for 7 days
before the telemetric recordings started. Post-surgical care included antibiotic
treatment (enroﬂoxacin 2.5–5 mg kg  1, subcutaneously) for 5 days and management of pain with Rimadyl tablets (2 mg). The locomotor and temperature signals
were wirelessly collected by a radio receiver (PhysioTel RPC-1, Data Sciences
International) placed on the bottom of each mouse cage. The signals were transferred to data matrixes (PhysioTel Multiplus Analog Adaptor Model DL-10, Data
Sciences International) that ampliﬁed and converted the analogical signals to
digital data that was acquired continuously in real time at 250 Hz, using the
computer-based Dataquest ART acquisition software (Data Sciences International).
The acquired data were analysed using Neuroscore (Data Sciences International)
and the sum of arbitrary counts of locomotor activity obtained for the 2 h following
vehicle or compound administration was presented. Core body temperature was
monitored over 24 h.
Social interaction assay. C57BL/6J mice were used in this experiment. They were
administered 100 mg kg  1 SR9011 or vehicle i.p. b.i.d. for 5 days and were tested
in the social interaction test 1 h following the ﬁnal injection. This test was originally
developed to model in mice aspects of autism spectrum disorders in humans68,69
and has been used widely by behavioural neuroscientists70. In addition, the SIA
assay has been used as a model for social anxiety disorder51. The social interaction
apparatus is a rectangular, three-chambered Plexiglas box, with each chamber
12

measuring 20 cm  40.5 cm  22 cm (L  W  H). Dividing walls are clear with
small semicircular openings (3.5 cm radius) allowing access into each chamber. The
middle chamber is empty, and the two outer chambers contain small, round wire
cages (Galaxy Cup, Spectrum Diversiﬁed Designs, Inc., Streetsboro, OH) during
testing. The mice were habituated to the entire apparatus with the round wire cages
removed for 5 min. Mice were familiarized with a stranger mouse (B6 of the same
sex being tested, habituated to the wire cage) in one of the wire cages in an outer
compartment and another identical wire cage in the opposite compartment for
5 min, followed by removal for 5 min before initiating the test. For the assay, mice
were returned to the middle chamber, this time with the original familiar mouse in
its chamber and a new unfamiliar mouse (novel mouse) in the previously empty
wire cage. Time spent in each chamber was recorded for 5 min. Twelve mice were
assessed per group.

Statistical analysis. All data are expressed as the mean±s.e.m. (N as indicated in
the ﬁgure legends). Statistical test used to determine signiﬁcant differences between
treatment groups are indicated in the ﬁgure legends. Variance within groups was
assessed by calculation of s.d. and variance was similar between groups that were
compared. For all in vivo experiments, the treatment groups were blinded to the
investigator. Mice were randomized to treatment groups, to control of potential
effects of cage mates and litter effects. Group sizes for particular experiments were
based on potential levels of efﬁcacy compared with known positive controls (for
example, chlordiazepoxide or cocaine) and power analysis. Normal distribution
was conﬁrmed for all experimental groups.
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